Back to search

Article

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

2023-11-29

Abstract excerpt

<title>Abstract</title> <p>This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab–paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 patients receiving nanoliposomal irinotecan + 5-fluorouracil/folinic acid (Nal-IRI + 5-FU/LV) (n = 102), S-1 (n = 57), or FOLFIRINOX...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e777a781-9fa1-5285-9a7e-7886b8c79e9a
DOI
10.21203/rs.3.rs-3607603/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxelDOI 10.21203/rs.3.rs-3607603/v1
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.Semantic proximity
Prognostic Nomogram for Patients With Unresectable Pancreatic Cancer Treated With Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX: Real-world Results From a Multicenter Retrospective Study (NAPOLEON study).Semantic proximity
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialSemantic proximity
Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiotherapy With Non-V600 BRAF Mutation Locally Advanced Pancreatic CancerSemantic proximity
The Second-Generation Proteasome Inhibitor Ixazomib Enhances the Anticancer Effects of Gemcitabine or Fluorouracil in Pancreatic Cancer CellsSemantic proximity
P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cellsSemantic proximity
PD-1 Inhibitor Plus Chemotherapy Versus Chemotherapy for First-Line Treatment in Advanced Esophageal Cancer: A Systematic Review and Meta-Analysis.Semantic proximity
Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world studySemantic proximity
Comparing the efficacy of five first-line treatment regimens for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trialsSemantic proximity
Results and molecular correlates from a pilot study of neoadjuvant induction FOLFIRINOX followed by chemoradiation and surgery for gastroesophageal adenocarcinomasSemantic proximity
Real life data and outcome of FOLFIRINOX use in metastatic pancreatic cancer patients in general hospitals in the NetherlandsSemantic proximity
Apaf1 nanoLuc biosensors identified lentinan as a potent synergizer of cisplatin in targeting hepatocellular carcinoma cells.Semantic proximity
Select a neighboring publication to make it the new centre.